Business
Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting
Nine scientific posters will illustrate the application of optical genome mapping (OGM) in cancer research areas including hematological malignancies, solid
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Nine scientific posters will illustrate the application of optical genome mapping (OGM) in cancer research areas including hematological malignancies, solid tumors, and applications in cell and gene therapy, cell manufacturing and bioprocessing quality controlBionano is introducing its new Stratys™ system for high throughput OGM to the cancer research communityBionano will preview VIA™ 7.1 software, an upcoming advancement to the Company’s software for visualization, interpretation and reporting of OGM, next-generation sequencing (NGS) and microarray data. VIA 7.1 includes new and improved capabilities for cancer research including improved aneuploidy detection with variant allele fraction (VAF) as low as 5%, enhanced structural variant (SV) visualization with VIA Circos plots, quality scores for SV detection, and streamlined interpretation with automated classification SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2024 with a broad range of content covering the utility of OGM for cell bioprocessing quality control, solid tumor and hematological malignancy cancer research. AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine. The AACR conference will be held April 5-10, 2024, in San Diego, California. Bionano will introduce its new Stratys™ system, which offers higher throughput and improved sample flexibility, to the cancer research community at the conference. The Company will also preview VIA™ 7.1 software, an upcoming advancement to its software for visualization, interpretation and reporting of OGM, NGS, and microarray data. VIA 7.1 includes new and improved capabilities for cancer research, including automated detection and interpretation of aneuploidies at a 5% variant allele fraction, providing researchers with greater insights into tumor initiation, progression and treatment resistance. The software also features quality scores for SV detection, enhanced visualization for accurate interpretation of complex datasets with VIA Circos plots, and streamlined, customizable reporting options. Nine scientific poster presentations will illustrate OGM’s utility for cancer research in areas including solid tumo...